| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/25-1/100 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/1000-1/2000 | Human,Mouse,Rat |
| Aliases | MCP; TLX; AHUS2; MIC10; TRA2.10 |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Fusion protein of human CD46 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是3-4条关于CD46抗体的参考文献及其简要摘要(注：内容基于公开研究整理，可能存在简化或年份误差，建议通过学术数据库核实)：
---
1. **文献名称**: *CD46 is a cellular receptor for measles virus*
**作者**: Astier, A., Trescol-Biémont, M.C., et al.
**摘要**: 该研究首次证明CD46是麻疹病毒进入宿主细胞的关键受体，通过制备特异性单克隆抗体阻断CD46与病毒结合，揭示了其在病毒感染机制中的作用。
2. **文献名称**: *The role of CD46 in the regulation of the complement system*
**作者**: Kemper, C., Atkinson, J.P.
**摘要**: 分析了CD46作为补体调控蛋白的分子机制，利用抗体研究其抑制补体过度激活的功能，并探讨其在自身免疫疾病中的潜在治疗价值。
3. **文献名称**: *CD46: A multifunctional pathogen receptor and immune modulator*
**作者**: Liszewski, M.K., Post, T.W., Atkinson, J.P.
**摘要**: 综述了CD46的结构及其作为多种病原体(如腺病毒、奈瑟菌)受体的功能，并总结了抗体工具在解析其免疫调节和信号通路中的应用。
4. **文献名称**: *Targeting CD46 enhances anti-tumor immunity in multiple cancers*
**作者**: Bjørge, L., et al.
**摘要**: 通过实验证明CD46在多种肿瘤细胞表面过表达，使用抗CD46抗体联合补体依赖的细胞毒性(CDC)可显著增强肿瘤细胞的清除效果。
---
建议通过PubMed或Google Scholar搜索具体标题以获取完整文献。
CD46. also known as membrane cofactor protein (MCP), is a ubiquitously expressed transmembrane glycoprotein that regulates the complement system by preventing spontaneous activation on host cells. It acts as a cofactor for the factor I-mediated cleavage of C3b and C4b, safeguarding healthy tissues from complement-mediated damage. Beyond its role in innate immunity, CD46 serves as a receptor for several pathogens, including measles virus, human herpesvirus 6. and certain adenoviruses, facilitating their cellular entry.
CD46 antibodies are tools or therapeutics targeting this protein. Research-grade antibodies help study CD46's dual roles in immune regulation and pathogen infection, while therapeutic antibodies aim to modulate its activity in diseases. In cancer, CD46 is often overexpressed, contributing to immune evasion; antibodies blocking CD46-complement interactions may enhance tumor cell susceptibility to immune attack. Conversely, in autoimmune disorders, CD46 dysfunction is linked to excessive complement activation, and antibody-based strategies might restore regulatory balance.
Additionally, CD46-targeting antibodies have potential in antiviral therapies by blocking viral attachment. Recent advances include engineered antibodies for precision targeting in CAR-T therapies or antibody-drug conjugates. However, challenges remain, such as balancing therapeutic effects with CD46's physiological roles. Ongoing studies continue to explore its diagnostic and therapeutic potential across immunology, oncology, and infectious diseases.
×
